The Board of Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announce the appointment of Matrix Corporate Capital LLP as joint broker with immediate effect.
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc
John Bick/Kirsty Corcoran - Hansard Communications
Ross Andrews/Tom Rowley - Zeus Capital - Nominated Adviser/Joint Broker
Robert Naylor/Stephen Waterman - Matrix Corporate Capital LLP - Joint Broker
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Sign up to our newsletter to stay up to date with Scancell